Sanofi announced on Nov. 15, 2024 that it has invested €40 million (US$42 million) in its Lyon Gerland bioproduction site in France. Of that amount, €25 million (US$26 million) is being dedicated to the production and development of the second generation of Thymoglobulin (anti-thymocyte globulin [rabbit]), the company’s polyclonal antibody used in the treatment of transplant patients. Source: Biopharm International 21/11/2024